Osteonecrosis of jaw caused by denosumab: A case report and literature review

doi:10.3877/cma.j.issn.1674-1366.2022.03.008

Abstract

Abstract:

Denosumab is an all human monoclonal antibody (IgG2) , which was first listed in the EU in 2010 approved for the treatment of osteoporosis in postmenopausal women and men at high risk of fractures. It was approved to be listed in China in June 2020 for the treatment of osteoporosis, but the clinicians in China have little experience in the application of denosumab. At present, there is no report of osteonecrosis of jaw caused by denosumab in China. This paper introduces a case report of osteonecrosis of jaw caused by denosumab, and reviews the literature for the reference of oral clinicians.

Key words: Denosumab, Jaw, Osteonecrosis, Osteoporosis, Bisphosphonates

Ming Wang, Ping Chen. Osteonecrosis of jaw caused by denosumab: A case report and literature review[J]. Chinese Journal of Stomatological Research(Electronic Edition), 2022, 16(03): 180-183.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhkqyxyjzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1366.2022.03.008

https://zhkqyxyjzz.cma-cmc.com.cn/EN/Y2022/V16/I03/180

Figures/Tables 2

References 15

[1]	Marx RE. Pamidronate（Aredia）and zoledronate（Zometa）induced avascular necrosis of the jaws：A growing epidemic[J]. J Oral Maxillofac Surg，2003，61(9):1115-1117. DOI：10.1016/s0278-2391(03)00720-1.
[2]	Kendler DL, Cosman F, Stad RK，et al. Denosumab in the treatment of osteoporosis：10 years later：A narrative review[J]. Adv Ther，2022，39(1):58-74. DOI：10.1007/s12325-021-01936-y.
[3]	Khan AA, Morrison A, Kendler DL，et al. Case-based review of osteonecrosis of the jaw（ONJ）and application of the international recommendations for management from the International Task Force on ONJ[J]. J Clin Densitom，2017，20(1):8-24. DOI：10.1016/j.jocd.2016.09.005.
[4]	Ruggiero SL, Dodson TB, Fantasia J，et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw：2014 update[J]. J Oral Maxillofac Surg，2014，72(10):1938-1956. DOI：10.1016/j.joms.2014.04.031.
[5]	Wick A, Bankosegger P, Otto S，et al. Risk factors associated with onset of medicationrelated osteonecrosis of the jaw in patients treated with denosumab[J]. Clin Oral Investig，2022，26(3):2839-2852. DOI：10.1007/s00784-021-04261-4.
[6]	Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy[J]. Br J Oral Maxillofac Surg，2010，48(3):221-223. DOI：10.1016/j.bjoms.2009.08.030.
[7]	Nakamura Y, Kikuiri T, Sugiyama T，et al. Anti-RANKL inhibits thymic function and causes DRONJ in mice[J]. Int J Dent，2022:9299602. DOI：10.1155/2022/9299602.
[8]	Papapoulos S, Chapurlat R, Libanati C，et al. Five years of denosumab exposure in women with postmenopausal osteoporosis：Results from the first two years of the FREEDOM extension[J]. J Bone Miner Res，2012，27(3):694-701. DOI：10.1002/jbmr.1479.
[9]	牛晓辉，刘巍峰.地舒单抗临床应用安全性的思考[J].中国骨与关节杂志，2018，7(9):641-645. DOI：10.3969/j.issn.2095-252X.2018.09.001.
[10]	Aldhalaan NA, BaQais A, Al-Omar A. Medication-related osteonecrosis of the jaw：A review[J]. Cureus，2020，12(2):e6944. DOI：10.7759/cureus.6944.
[11]	Eguia A, Bagán-Debón L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw[J]. Med Oral Patol Oral Cir Bucal，2020，25(1):e71-e83. DOI：10.4317/medoral.23191.
[12]	Mollica V, Nuvola G, Tassinari E. Bone targeting agents in patients with prostate cancer：General toxicities and osteonecrosis of the jaw[J]. Curr Oncol，2022，29(3):1709-1722. DOI：10.3390/curroncol29030142.
[13]	杨涛，魏建华，雷德林，等.药物相关性颌骨坏死的研究进展[J].现代肿瘤医学，2020，28(6):1039-1042. DOI：10.3969/j.issn.1672-4992.2020.06.038.
[14]	Soma T, Iwasaki R, Sato Y，et al. Osteonecrosis development by tooth extraction in zoledronate treated mice is inhibited by active vitamin D analogues，antiinfammatory agents or antibiotic[J]. Sci Rep，2022，12(1):19. DOI：10.1038/s41598-021-03966-6.
[15]	Ali IE, Sumitaa Y. Medication-related osteonecrosis of the jaw：Prosthodontic considerations[J]. Jpn Dent Sci Rev，2022，58:9-12. DOI：10.1016/j.jdsr.2021.11.005.

Please choose a citation manager

Content to export